MedTrace Logo

Bypass Surgery Versus Everolimus-Eluting Stent Implantation for Multivessel Coronary Artery Disease (BEST)

NCT00997828 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 888

Last updated 2019-05-10

No results posted yet for this study

Summary

The purpose of this study is to determine whether the safety and efficacy of coronary stent implantation using Everolimus-Eluting Coronary Stent System (Abbott, Boston Scientific) is not inferior to coronary artery bypass grafting (CABG) for the treatment of patient with multivessel coronary artery disease (CAD).

Conditions

Interventions

DEVICE

everolimus-eluting stent

Xience V stent

PROCEDURE

coronary artery bypass graft surgery

coronary artery bypass graft surgery

Sponsors & Collaborators

  • Abbott Medical Devices

    collaborator INDUSTRY

  • CardioVascular Research Foundation, Korea

    collaborator OTHER

  • Seung-Jung Park

    lead OTHER

Principal Investigators

  • Seung-Jung Park, MD, PhD · Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-28
Primary Completion
2016-04-30
Completion
2019-04-05

Countries

  • China
  • Malaysia
  • South Korea
  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00997828 on ClinicalTrials.gov